The respiratory disease drug developer has collected series A funding from investors including Shionogi to fund clinical trials of its lead drug candidate .

Vast Therapeutics, a US-based developer of respiratory disease therapies based on research at University of North Carolina (UNC) at Chapel Hill, has secured $15m in a series A round that included pharmaceutical firm Shionogi, Wral TechWire has reported. The company revealed it had raised funding last month without giving a precise amount. It has also…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.